Skip to main content
Harbin Pharmaceutical Group Co.,Ltd. logo

Harbin Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 600664 ISIN · CNE0000009T3 LEI · 300300G0L086UJ23MI26 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,826 across all filing types
Latest filing 2022-02-21 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 600664

About Harbin Pharmaceutical Group Co.,Ltd.

https://www.hayao.com/

Harbin Pharmaceutical Group Co., Ltd. specializes in the research, development, manufacture, and distribution of a diverse range of pharmaceutical and healthcare products. The company's portfolio includes antibiotics, over-the-counter (OTC) medicines, health supplements, traditional Chinese medicines, and animal health products. It operates through several specialized subsidiaries and maintains a significant presence in the production of penicillins and cephalosporins. A key strategic focus involves the health and nutrition sector, bolstered by the acquisition of global nutrition brand GNC. The company leverages large-scale manufacturing capabilities and an extensive distribution network to serve both domestic and international markets. Its operations emphasize technological innovation and quality control across its integrated supply chain, from raw material production to finished dosage forms.

Recent filings

Filing Released Lang Actions
哈药集团股份有限公司独立董事关于公司九届二十一次董事会相关事项的独立意见
Board/Management Information Classification · 85% confidence The document is an independent directors' opinion on a board meeting matter related to the company's stock incentive plan, including the granting of stock options and restricted shares. It references compliance with company law, securities law, and stock exchange rules, and discusses governance and approval processes. The document is not a full financial report, earnings release, or regulatory filing but rather a formal opinion related to board decisions and governance matters. It does not announce voting results or changes in management but focuses on governance and board-related opinions. Therefore, it fits best under Board/Management Information (MANG) as it relates to board decisions and governance matters.
2022-02-21 Chinese
哈药集团股份有限公司九届二十一次董事会决议公告
Board/Management Information Classification · 95% confidence The document is a board resolution announcement from Harbin Pharmaceutical Group Co., Ltd. regarding the approval of stock options and restricted stock grants to incentive recipients. It includes details about the meeting date, voting results, and references to related regulatory filings on the Shanghai Stock Exchange website. The content focuses on a board decision about equity incentives, which is a management/board information disclosure rather than a full financial report or earnings release. The document length is short (733 characters), and it is a formal announcement of a board resolution, fitting the category of Board/Management Information (MANG).
2022-02-21 Chinese
北京安杰（上海）律师事务所关于哈药集团股份有限公司2021年股票期权与限制性股票激励计划预留部分授予相关事宜之法律意见书
Regulatory Filings
2022-02-21 Chinese
哈药集团股份有限公司监事会关于公司2021年股票期权与限制性股票激励计划剩余预留部分授予事项的核查意见
Regulatory Filings Classification · 95% confidence The document is a formal opinion from the supervisory board regarding the verification of the remaining reserved portion of a 2021 stock option and restricted stock incentive plan. It discusses compliance with relevant laws and regulations, qualifications of incentive recipients, and details of the stock option and restricted stock grants. The content focuses on the approval and verification of stock incentive awards rather than financial results, management changes, or general meeting materials. It is not an announcement of voting results or a proxy solicitation. The document is not a full financial report or earnings release but rather a regulatory compliance and internal governance matter related to stock incentives. Therefore, it fits best under Regulatory Filings (RNS) as it is a compliance-related announcement that does not fit other specific categories.
2022-02-21 Chinese
宁波小多信息咨询有限公司关于哈药集团股份有限公司2021年股票期权与限制性股票激励计划预留授予相关事项之独立财务顾问报告
Capital/Financing Update Classification · 95% confidence The document is an Independent Financial Advisor Report related to the 2021 stock option and restricted stock incentive plan of 哈药集团股份有限公司 (Harbin Pharmaceutical Group Co., Ltd.). It includes detailed explanations of the stock option and restricted stock plans, approval procedures, grant conditions, performance targets, and the impact on financial results. The document is lengthy (over 13,000 characters) and contains substantive financial and operational details about the incentive plan. It is not a simple announcement or a brief summary but a comprehensive advisory report on a capital incentive plan. This type of document fits best under the category of Capital/Financing Update (CAP), as it deals with stock option grants and equity incentives which affect the company's capital structure and financing arrangements. It is not an Annual Report, Audit Report, or Management Report, nor is it a regulatory filing or announcement. Therefore, the most appropriate classification is CAP with high confidence.
2022-02-21 Chinese
哈药集团股份有限公司2021年股票期权与限制性股票激励计划剩余预留部分授予激励对象名单(授予日)
Share Issue/Capital Change Classification · 95% confidence The document is a detailed announcement of the allocation of stock options and restricted stock under a 2021 stock incentive plan for specific individuals within the company. It includes names, positions, quantities of stock options and restricted stock granted, and percentages relative to total stock. The document is issued by the company's board and dated February 21, 2022. There is no indication that this is a full financial report, audit, or earnings release. Instead, it is a disclosure related to share-based compensation and stock incentive plans, which typically falls under announcements related to share issues or capital changes. The document is not a proxy solicitation, remuneration report, or management report, but specifically details stock option and restricted stock grants. Therefore, the most appropriate classification is Share Issue/Capital Change (SHA). The document length is short (1169 characters), but it contains substantive data about stock option and restricted stock grants, not just an announcement of a report publication or a certification, so it is not RPA or RNS.
2022-02-21 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.